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Part of circulating ghrelin is bound to immunoglobulins (Ig) protecting it from 
degradation and preserving its functional activity. This review summarizes the data on 
ghrelin- and desacyl-ghrelin-reactive IgG in conditions of altered appetite and energy 
balance. Plasma levels and affinity kinetics of such IgG were compared in patients 
with obesity and anorexia nervosa (AN) and in animal models of obesity including ob/
ob mice, high-fat diet-induced obese mice, and obese Zucker rats as well as in mice 
after chronic food restriction and activity-based anorexia and in rats with methotrexate-
induced anorexia. We show that plasmatic IgG in both obese humans and animals 
are characterized by increased affinity for ghrelin. In contrast, patients with AN and 
anorectic rodents all show lower affinity of ghrelin- and desacyl-ghrelin-reactive IgG, 
respectively, the changes which were not observed in non-anorectic, chronically 
starved mice. We also show that affinity of ghrelin-reactive IgG correlate with plasma 
levels of ghrelin. These data point to common mechanisms underlying modifications 
of affinity kinetics properties of ghrelin-reactive IgG during chronic alterations of energy 
balance in humans and rodents and support a functional role of such autoantibodies in 
ghrelin-mediated regulation of appetite.
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iNTRODUCTiON
Ghrelin is a 28 amino acid acylated enteroendocrine peptide produced mainly in the stomach, 
which has been isolated and named based on its ability to stimulate growth hormone secretion (1). 
One of the main properties of ghrelin, independent from growth hormone secretagogue activity, is 
stimulation of feeding and body weight gain (2–4). Importantly, acylation of the serine 3 residue 
in the ghrelin’s N-terminal by octanoic acid is necessary for binding of the growth hormone 
secretagogue receptor 1 (GHSR1), designated as ghrelin receptor (5) and biological activity including 
stimulation of food intake (6–8). However, the active, acylated form of ghrelin is unstable in the 
circulation and is degraded to desacyl-ghrelin (9, 10). The half-life pharmacokinetics properties of 
acyl-ghrelin in human plasma are about 10 min (11). The preservation of the acylated ghrelin form 
in the circulation appears, hence, as a key factor for maintaining its role in regulation of appetite 
and energy balance. Several mechanisms are involved in the regulation of ghrelin signaling during 
its production and receptor activation, which can be exploited for development of ghrelin-based 
therapy of altered appetite (12). Recently, a new regulatory factor of the ghrelin signaling has been 
identified, which is ghrelin-reactive immunoglobulins (Ig)  (13). This review is the first attempt 
to summarize the data on ghrelin-reactive IgG obtained since their initial identification and the 
following studies in animal models of altered appetite and energy balance.
TABle 1 | Plasma concentrations of acyl-ghrelin and desacyl-ghrelin in 
humans and rodents.
Acyl-ghrelin (pM) Desacyl-ghrelin (pM) Acyl/
desacyl-
ghrelin 
ratio
Mean ± SeM
OB 24.88 ± 5.81 ns 137.7 ± 16.07 ns 1:6 $
AN 52.67 ± 7.14 $$$ 249.1 ± 38.32 $$$ 1:4 ns
Ctrl 25.65 ± 3.58 114.7 ± 29.24 1:3
ob/ob 10.36 ± 0.96 # 75.17 ± 10.31 * 1:7 ns
Ctrl 13.02 ± 0.90 120.4 ± 17.32 1:8
HFD 10.21 ± 0.95 ns 117.3 ± 9.75 ** 1:10 ns
Ctrl 11.92 ± 1.45 196.5 ± 27.95 1:13
Zucker 17.18 ± 1.59 ns 444.8 ± 33.86 * 1:25 ns
Ctrl 16.20 ± 4.38 242.0 ± 55.80 1:16
ABA 21.58 ± 6.86 ns 1331.0 ± 87.52 $$ 1:63 ns
FTR 17.82 ± 5.02 ns 1221.0 ± 120.7 $ 1:71 $
Ctrl 9.14 ± 2.50 195.8 ± 22.50 1:17
MTX 12.68 ± 2.21 ** 698.8 ± 95.8 * 1:46 ns
Ctrl 7.44 ± 1.08 352.4 ± 27.79 1:46
Human patients: OB, obese; AN, anorexia nervosa. Rodent models of obesity: ob/
ob mice; HFD, high fat diet-induced obese mice and Zucker rats. Rodent models 
of anorexia and starvation: ABA, activity-based anorexia in mice; FTR, feeding-time 
restriction in mice; and MTX, methotrexate-induced anorexia in rats. Ctrl, healthy 
human or rodent controls in corresponding row. Student’s t-test or Mann–Whitney test, 
*p < 0.05; **p < 0.01; #p < 0.10. ANOVA with Tukey’s posttest or Kruskal–Wallis with 
Dunn’s posttest $p < 0.05, $$p < 0.01, $$$p < 0.001.
2
Fetissov et al. Ghrelin-Reactive IgG and Appetite
Frontiers in Endocrinology | www.frontiersin.org January 2017 | Volume 8 | Article 10
MeTHODS
The review focuses mainly on the data from five papers, all report-
ing affinity kinetics of ghrelin- and desacyl-ghrelin-reactive IgG. 
They include a study of patients with hyperphagic obesity and 
anorexia nervosa (AN) and of ob/ob mice by Takagi et al. (13); two 
studies by François et al. in high-fat diet (HFD)-induced obese 
mice (14) and in rats with methotrexate (MTX)-induced anorexia 
(15), a study by Lucas et al. in obese Zucker rats (16) as well as 
a Legrand et al. study in mice after chronic food-restriction and 
activity-based anorexia (17). In all mentioned studies, the same 
protocols of IgG plasma extraction and affinity kinetic assay by the 
surface plasmon resonance were used as was previously described 
in details (18). All measurements of ghrelin and desacyl-ghrelin 
peptides in above mentioned studies were performed using cor-
responding kits from Mitsubishi Chemical Med Corp. (Tokyo, 
Japan), selectively detecting acyl- and desacyl-ghrelin with result-
ing plasma ratios of 1:3 to 1:6 in humans. In the text, we use the 
terms of ghrelin and acyl-ghrelin as synonyms. For the statistical 
analysis of ghrelin and ghrelin-reactive IgG properties between 
different animal models and patients, they are shown as means of 
folds of changes vs. corresponding controls. In this analysis, we 
combined two animal models of anorexia including ABA mice 
and MTX rats and three animal models of obesity including ob/
ob mice, HFD-induced obese mice, and obese Zucker rats. Group 
differences shown in Tables  1–4 and Figure  1 were analyzed 
using statistical tests indicated in the legends. We also used the 
Pearson’s test to analyze correlations between plasma levels of 
ghrelin or desacyl-ghrelin and plasma levels and affinity (KD 
values) of corresponding IgG.
DeTeCTiON OF GHReliN-ReACTive igG
Ghrelin-reactive IgG were first shown to be naturally present 
in plasma of healthy humans and rodents in 2008 by Fetissov 
et  al. (19). Further studies confirmed and extended this initial 
finding by including female patients with restrictive AN (20) and 
with hyperphagic obesity (13). Moreover, a study using plasma 
samples of a large number of healthy male (n = 562) and female 
(n =  636) adolescents also revealed an ubiquitous presence of 
ghrelin-reactive autoantibodies of both IgG and IgM classes, 
which mean plasma levels were slightly elevated in girls vs. boys 
(21). In rodents, ghrelin-reactive IgG were detected in both rats 
(15, 19) and mice (13, 14, 17). Since the rodents studies were 
performed only in males, presence of possible sex differences of 
ghrelin-reactive IgG was not explored. However, it is likely that 
similarly to humans they may also be increased in female rodents 
who naturally display elevated plasma levels of total IgG and IgM 
as well as increased levels of autoantibodies reactive with other 
neuropeptides, e.g., α-melanocyte-stimulating hormone (α-
MSH) (22).
Ghrelin-reactive IgG were also measured in the hypothalamic 
and liver tissue of C57Bl6 mice, showing their levels at the limit of 
detection (13). However, if levels of ghrelin-reactive IgG in these 
tissues of lean mice were stratified according to their exposure 
to a restraint stress in an EchoMRI instrument, which they had 
undergone prior to tissue sample for the analysis of their body 
composition, an increase is observed in both tissues and a decrease 
in plasma of stressed animals. It suggests that ghrelin-reactive IgG 
may help transportation of ghrelin mobilized during stress from 
plasma to its tissue targets.
Desacyl-ghrelin-reactive IgG are also present in humans (13, 
20) and rodents (15, 17). Although some part of desacyl-ghrelin-
reactive IgG may bind to acyl-ghrelin, they should also have 
distinct paratopes, because levels of desacyl-ghrelin IgG are often 
higher than of acyl-ghrelin IgG in human plasma (13, 20) and 
also because they have different affinity kinetics properties (13). 
The exact epitopes responsible for plasma IgG binding to ghrelin 
and desacyl-ghrelin remain to be been studied.
Both “free” and “total” ghrelin- and desacyl-ghrelin-reactive 
IgG are detected in plasma of humans and rodents. While “free” 
IgG are measured in physiological buffer, the “total” levels are 
measured in a high salt buffer, which dissociate immune com-
plexes typically resulting in increased “total” vs. “free” levels of 
IgG. Accordingly, increased levels of free/total ratios may reflect 
an increase in IgG available to bind ghrelin or desacyl-ghrelin 
(Table 2).
ORiGiN AND ReGUlATiON OF GHReliN-
ReACTive igG
Ghrelin-reactive IgG are natural autoantibodies and, therefore, are 
produced by germ-like B-cells as a part of native immunity (23). 
As was postulated by Avrameas, natural autoantibodies may 
participate in a complex regulatory network, not necessarily 
TABle 3 | Affinity kinetics of acyl-ghrelin-reactive igG in humans and rodents.
Acyl-ghrelin-reactive igG
Ka (1/Ms) Kd (1/s) KD (M)
Mean ± SeM
AN 9.36E+04 ± 2.23E+03 ns 3.25E−03 ± 8.04E−04 $ 4.86E−07 ± 1.20E−07 §§
OB 2.23E+04 ± 1.16E+04 $ 1.86E−03 ± 3.04E−04 ns 1.91E−07 ± 1.48E−08 ns
Ctrl 6.84E+03 ± 1.19E+03 1.49E−03 ± 1.14E−04 2.54E−07 ± 2.81E±08
ob/ob 1.01E+05 ± 9.46E+03 ns 1.81E−03 ± 7.81E−05 ** 2.03E−08 ± 2.88E−09 *
Ctrl 8.89E+04 ± 9.08E+03 2.46E−03 ± 1.48E−04 3.02E−08 ± 3.57E−09
HFD 1.68E+04 ± 4.87E+03 ns 1.58E−03 ± 3.22E−04 ns 1.17E−07 ± 1.18E−08 **
Ctrl 1.04E+04 ± 2.06E+03 2.02E−03 ± 2.82E−04 2.55E−07 ± 4.51E−08
Zucker 1.01E+04 ± 1.54E+03 ns 1.22E−03 ± 1.61E−04 * 1.36E−07 ± 2.65E−08 *
Ctrl 7.93E+03 ± 6.53E+02 1.70E−03 ± 9.79E−05 2.24E−07 ± 2.50E−08
ABA 4.72E+04 ± 8.12E+03 *,£ 5.11E−04 ± 1.07E−04 ns 1.24E−08 ± 2.83E−09 ns
FTR 2.03E+04 ± 6.62E+03 ns 2.51E−04 ± 1.32E−04 ns 1.38E−08 ± 5.61E−09 ns
Ctrl 1.48E+04 ± 5.58E+03 2.45E−03 ± 1.15E−04 1.52E−08 ± 6.15E−09
MTX 2.00E+03 ± 6.30E+02 ns 1.29E−03 ± 2.28E−04 * 1.18E−07 ± 4.92E−07 ns
Ctrl 1.79E+03 ± 5.06E+02 5.97E−04 ± 1.92E−04 5.73E−07 ± 2.49E−08
Human patients: OB, obese; AN, anorexia nervosa. Rodent models of obesity: ob/ob mice; HFD, high fat diet-induced obese mice and Zucker rats. Rodent models of anorexia 
and starvation: ABA, activity-based anorexia in mice; FTR, feeding-time restriction in mice; and MTX, methotrexate-induced anorexia in rats. Ctrl, healthy human or rodent controls 
in corresponding row. ANOVA with Tukey’s posttest or Kruskal–Wallis test with Dunn’s posttest, $p < 0.05; AN vs. OB §§p < 0.01. Student’s t-test or Mann–Whitney test vs. Ctrl 
*p < 0.05; **p < 0.01, vs. RFA £p < 0.05.
TABle 2 | Plasma levels of igG reactive with acyl-ghrelin and desacyl-ghrelin in humans and rodents.
Acyl-ghrelin-reactive igG Desacyl-ghrelin-reactive igG Acyl-ghrelin-
reactive igG
Desacyl-
ghrelin-
reactive igG
Free Total Free Total Free/total 
ratio
Free/total 
ratio
Mean ± SeM
OB 0.291 ± 0.050 ns 0.617 ± 0.054 $ 0.563 ± 0.049 ns 1.250 ± 0.057 ns 1:2.1 $ 1:2.3 ns
AN 0.288 ± 0.020 ns 0.753 ± 0.049 ns 0.643 ± 0.054 ns 1.364 ± 0.080 ns 1:2.5 ns 1:2.1 ns
Ctrl 0.264 ± 0.020 0.918 ± 0.103 0.584 ± 0.094 1.384 ± 0.101 1:3.2 1:2.4
ob/ob 0.133 ± 0.025 * 0.098 ± 0.013 # n.a. n.a. 1:0.6 ns n.a.
Ctrl 0.207 ± 0.024 0.162 ± 0.028 n.a. n.a. 1:0.8 n.a.
HFD 0.504 ± 0.050 ns 0.450 ± 0.033 ** n.a. n.a. 1:0.8 ns n.a.
Ctrl 0.589 ± 0.067 0.624 ± 0.059 n.a. n.a. 1:0.9 n.a.
Zucker 0.268 ± 0.062 * 0.235 ± 0.073 * 0.244 ± 0.048 # 0.241 ± 0.066 * 1:0.6 * 1:0.8 *
Ctrl 0.715 ± 0.206 1.061 ± 0.259 0.627 ± 0.165 0.975 ± 0.225 1:1.5 1:1.5
ABA 0.258 ± 0.084 ns 0.340 ± 0.127 ns 0.226 ± 0.091 ns 0.366 ± 0.127 ns 1:1.5 £ 1:1.4 ns
FTR 0.187 ± 0.045 0.459 ± 0.109 0.242 ± 0.062 0.501 ± 0.127 1:2.4 1:2.0
Ctrl 0.172 ± 0.052 0.315 ± 0.043 0.238 ± 0.069 0.464 ± 0.080 1:1.9 1:2.0
MTX 0.063 ± 0.016 * 0.041 ± 0.007 *** 0.070 ± 0.015 * 0.031 ± 0.006 *** 1:0.6 *** 1:0.4 ***
Ctrl 0.188 ± 0.043 0.319 ± 0.044 0.223 ± 0.048 0.271 ± 0.036 1:1.7 1:1.2
Human patients: OB, obese; AN, anorexia nervosa. Rodent models of obesity: ob/ob mice; HFD, high fat diet-induced obese mice and Zucker rats. Rodent models of anorexia and 
starvation: ABA, activity-based anorexia in mice; FTR, feeding-time restriction in mice; and MTX, methotrexate-induced anorexia in rats. Ctrl, healthy human or rodent controls in 
corresponding row. Student’s t-test or Mann–Whitney test, *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.10. ANOVA with Tukey’s posttest or Kruskal–Wallis test with Dunns’ posttest, 
$p < 0.05; ABA vs. FTR £p < 0.05.
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directly related to the immune function but contributing to the 
homeostatic control (24). The production and affinity maturation 
of IgG are influenced by a variety of antigens and non-specific 
immune-stimulatory or inhibitory factors such as cytokines 
and steroid hormones. Moreover, increased plasma levels of 
ghrelin-reactive IgG in rats can be induced acutely by gastric 
electrical stimulation (25), suggesting that they can be stored 
and released upon a physiological stimulus. It is of interest 
that gastric electrical stimulation activated c-fos production in 
numerous lymphoid cells of the gastric mucosa surrounding the 
enteroendocrine ghrelin-synthetizing cells (26). Strong inhibi-
tion of ghrelin-reactive IgG levels in plasma is observed in rats 
after treatment with MTX, an immunosuppressive agent, which 
induces intestinal mucositis (15).
FiGURe 1 | Relative to control (Ctrl) values (1.0) changes in plasma 
ghrelin and desacyl ghrelin as well as affinity of their reactive igG in 
patients and animal models of obesity and anorexia. Changes in 
plasma levels of acyl-ghrelin (A) and desacyl-ghrelin (C). Changes in affinity 
(dissociation equilibrium constant, KD) of plasmatic IgG for acyl-ghrelin (B) 
and desacyl ghrelin (D). AN, anorexia nervosa patients; An, animal models of 
anorexia; OB, obese patients or animals. Mann–Whitney tests ***p < 0.001, 
**p < 0.01, and *p < 0.05.
TABle 4 | Affinity kinetics of desacyl-ghrelin-reactive igG in humans and rodents.
Desacyl-ghrelin-reactive igG
Ka (1/Ms) Kd (1/s) KD (M)
Mean ± SeM
AN 1.04E+04 ± 1.02E+03 ns 2.26E−03 ± 3.86E−04 ns 8.61E−07 ± 7.17E−08 ns
OB 2.21E+04 ± 9.80E+03 ns 1.74E−03 ± 4.16E−04 ns 1.47E−07 ± 1.69E−08 ns
Ctrl 1.21E+04 ± 1.28E+03 1.65E−03 ± 1.50E−04 1.51E−07 ± 1.56E−08
ob/ob 3.73E+03 ± 3.61E+03 # 7.23E−03 ± 8.10E−07 ns 9.59E−06 ± 3.76E−06 ns
Ctrl 1.89E+04 ± 9.33E+03 2.68E−05 ± 1.55E−05 4.13E−06 ± 3.38E−06
HFD 2.72E+03 ± 1.74E+03 ns 1.34E−04 ± 1.30E−04 * 3.79E−08 ± 1.47E−08 #
Ctrl 1.09E+04 ± 4.71E+03 8.39E−04 ± 3.03E−04 1.38E−07 ± 4.72E−08
Zucker 2.40E+04 ± 3.55E+03 ns 1.34E−03 ± 3.51E−04 * 6.78E−08 ± 2.30E−08 ns
Ctrl 2.85E+04 ± 4.24E+03 2.26E−03 ± 3.05E−04 9.88E−08 ± 2.21E−08
ABA 1.94E+04 ± 8.06E+03 ns 1.12E−03 ± 2.09E−04 $$ 9.20E−08 ± 2.34E−08 $
FTR 8.32E+03 ± 2.89E+03 ns 3.24E−04 ± 2.03E−04 ns 1.03E−07 ± 5.97E−08 ns
Ctrl 1.74E+04 ± 9.64E+03 2.07E−06 ± 1.20E−06 1.57E−08 ± 1.06E−09
MTX 2.56E+03 ± 1.55E+03 ns 2.01E−04 ± 1.33E−04 ns 6.97E−08 ± 1.73E−08 *
Ctrl 1.71E+02 ± 1.33E+02 1.05E−06 ± 2.16E−07 2.07E−08 ± 5.46E−09
Human patients: OB, obese; AN, anorexia nervosa. Rodent models of obesity: ob/ob mice; HFD, high fat diet-induced obese mice and Zucker rats. Rodent models of anorexia 
and starvation: ABA, activity-based anorexia in mice; FTR, feeding-time restriction in mice; and MTX, methotrexate-induced anorexia in rats. Ctrl, healthy human or rodent controls 
in corresponding row. ANOVA with Tukey’s posttest or Kruskal–Wallis test with Dunn’s posttest, $p < 0.05; $$p < 0.01. Student’s t-test or Mann–Whitney test, vs. Ctrl *p < 0.05; 
#p < 0.10.
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A particular role in production of IgG and other classes of 
Ig can be played by antigens derived from gut microbiota as a 
constitutive part of the gastro-intestinal tract in all animals (27). 
The gut bacterial antigens may also be involved in regulation 
of production and properties of ghrelin-reactive IgG. In fact, 
germ-free rats showed elevated plasma levels of ghrelin-reactive 
IgG (19), supporting a role of some intestinal antigens in toleriza-
tion toward ghrelin (28). The molecular basis linking microbial 
antigens with peptides may relate to the concept of molecular 
mimicry by cross-reactive autoantibody production (29). Indeed, 
sequence homology between ghrelin and several proteins from 
commensal gut microorganisms was shown, e.g., of seven 
consecutive amino acids present in a protein from Enterococcus 
faecalis (19). A role of molecular mimicry was recently validated 
as a mechanism underlying production of α-MSH-reactive IgG 
induced by caseinolytic peptidase B (ClpB) homolog protein 
from Escherichia coli (30). ClpB contains a discontinuous six 
amino acid homology with α-MSH; immunization of mice with 
ClpB generates α-MSH-cross reactive IgG (30). Plasma presence 
of the IgA class of ghrelin-reactive IgG also points to their origin 
triggered by luminal antigens (19).
Beside the stimulation of antigens from commensal gut 
microbiota, pathogenic and environmental microorganisms may 
possibly influence production of ghrelin-reactive IgG. In fact, 
plasma levels of ghrelin-reactive IgG in healthy adolescents cor-
relate strongly with both IgG and IgM directed against influenza 
A virus (21). Although the initial in  silico search for five con-
secutive amino acids sequence homology did not reveal matches 
between ghrelin and the Influenza viruses (19), a discontinuous 
eight amino acid homology for ghrelin is present in the PB1-F2 
influenza A protein.
Another example of ghrelin-reactive IgG comes from studies 
of children with idiopathic short stature by the Lewinski group. 
FiGURe 2 | examples of correlations between affinity and levels of ghrelin-reactive igG and plasma concentrations of acyl-ghrelin. Correlations 
between the values of dissociation equilibrium constants (KD) of plasmatic IgG reactive with ghrelin and acyl ghrelin in obese and anorectic patients and controls (A) 
and in ob/ob and lean mice (B). Correlations between plasma levels of ghrelin-reactive free IgG (C) as well as ratios of their free/total levels (D) in ob/ob and lean 
mice. Correlations between plasma levels of ghrelin-reactive total IgG in Zucker rats (e). R-squared and p-values for Pearson’s correlation tests are shown, 
**p < 0.01 and *p < 0.05.
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They showed that prevalence of high level IgG reactive with sev-
eral peptide hormones, including ghrelin, orexin A, leptin, and 
α-MSH combined, was associated with an increased incidence 
of Helicobacter pylori and/or Candida albicans (31). A follow-up 
study showed that mean plasma levels of ghrelin-reactive IgG 
were also elevated in children with short stature, but they were 
not significantly different in patients with growth hormone 
deficiency (32). Since H. pylori is only residing in the stomach, 
which is the main source of ghrelin, it is of interest to explore 
possible role of H. pylori in production of ghrelin-reactive IgG. In 
fact, cure of H. pylori in humans was accompanied by increased 
plasma levels of ghrelin (33).
FUNCTiONAl ROle OF GHReliN-
ReACTive igG
An established physiological role of IgG is to protect against 
infection including their ability to directly neutralize antigens 
and to trigger cell lysis via activation of the complement. While 
presence of IgG reactive with some peptide hormones have 
been detected in plasma of healthy humans (34), their possible 
functional role remained unknown, as previously reviewed (35). 
Ghrelin-reactive IgG were the first IgG revealing that they have 
a functional role in the peptide signaling by protecting ghrelin 
from degradation in plasma (13). In fact, as was shown by an 
in vitro assay, depletion of plasma from IgG resulted in an almost 
complete loss of acyl-ghrelin, while their reintroduction allowed 
its full recovery (13). Thus, the main functional role of ghrelin-
reactive IgG appears to protect ghrelin from degradation.
Such protection did not reduce the orexigenic activity of ghre-
lin, because administrations of ghrelin together with plasmatic 
IgG, stimulated food intake and even enhanced it when IgG were 
derived from plasma of obese humans or mice (13). Such enhanc-
ing effect was explained by a slight, about three times, increase of 
IgG affinity for ghrelin and the evidence that such IgG are able to 
transport more active ghrelin in obese patients. Moreover, the KD 
values of ghrelin-reactive IgG remained in the micromolar range, 
which would preclude their competition with the nanomolar 
affinity of ghrelin receptor binding (36).
We show here that KD values of IgG for ghrelin correlate 
positively with plasma ghrelin concentrations in obese and 
AN patients as well as in ob/ob mice (Figures  2A,B). These 
correlations demonstrate that a decrease in IgG affinity for 
ghrelin (increase in KD) corresponds to higher ghrelin levels 
and suggest that properties of ghrelin-reactive IgG may at least 
partly underlie individual differences in plasma ghrelin levels. 
An inverse relation is unlikely, because increased antigen con-
centration should stimulate the affinity maturation of IgG. We 
also find that plasma levels of ghrelin-reactive free IgG as well 
as ratios of free/total IgG levels correlate positively with plasma 
ghrelin (Figures 2C,D). In contrast, ghrelin-reactive total IgG 
correlate negatively with plasma ghrelin (Figure  2E). Taken 
together, these correlations support a carrier role of plasmatic 
IgG for ghrelin.
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Considering increased functional effects of ghrelin in immune 
complex with IgG vs. ghrelin alone, the accompanying changes in 
plasma ghrelin levels during altered energy metabolism can be a 
“mirror” reflection of the ghrelin’s functional activity. Accordingly, 
increased plasma levels of ghrelin, e.g., in AN patients and 
in animal models of anorexia (Figure  1), may signify ghrelin’s 
inability to form stable immune complexes with IgG and, hence, 
may result in a functional deficiency of the ghrelin signaling or 
“ghrelin resistance.” Such explanation may appear at first glance 
as paradoxical, but it gains further support from the corroborat-
ing data revealing an enhancing role of IgG in signaling by other 
peptide hormones such as α-MSH (37, 38).
Thus, the changes in IgG affinity kinetics resulting in a slight 
increase of affinity can be considered as a gain of function in 
ghrelin signaling. Taking in account important functional 
consequences of affinity changes in ghrelin-reactive IgG, it is 
clear that a simple measurement of their plasma levels is not 
sufficient and should be combined with the affinity kinetics 
analysis. Nevertheless, affinity changes should still be taken 
with caution as a putative biomarker, as long as we do not know 
if they involve or not any epitope changes that may prevent the 
availability of the ghrelin N-terminal, necessary for the GHSR1 
binding. We do not yet know if presence of IgG in immune 
complex with ghrelin may play an allosteric role in ghrelin 
receptor activation, a phenomenon suggested for IgG reactive 
with α-MSH (37, 38).
To summarize these data, presence of IgG at normal levels 
and with physiological micromolar affinity for ghrelin in humans 
appears as a homeostatic factor in regulation of ghrelin signaling. 
Accordingly, any changes in these factors should lead to altera-
tion of the ghrelin signaling with resulting effects on appetite and 
body weight regulation. Therefore, in order to facilitate the data 
interpretation toward an enhanced or diminished ghrelin signal-
ing, the following algorithm can be proposed.
For the enhanced ghrelin signaling one of several changes can 
be observed:
 – Increased plasma levels of ghrelin-reactive both free and 
total IgG;
 – Increased micromolar affinity of IgG for ghrelin;
 – Changes in affinity kinetics of IgG for ghrelin toward its 
increased binding including increased association rate (small 
Ka) and/or decreased dissociation rate (small Kd).
By the opposite, for the diminished ghrelin signaling, the fol-
lowing changes can be present:
 – Decreased plasma levels of ghrelin-reactive both free and 
total IgG;
 – Decreased micromolar affinity of IgG for ghrelin;
 – Changes in affinity kinetics of IgG for ghrelin toward its 
decreased binding including decreased association rate (small 
Ka) and/or increased dissociation rate (small Kd).
While the functional role of ghrelin-reactive IgG with regard 
to ghrelin’s orexigenic effect can be interpreted as facilitating, 
the corresponding role of IgG reactive with desacyl-ghrelin is 
uncertain. As discussed above, IgG may bind to the common cen-
tral and the C-terminal parts of ghrelin and desacyl-ghrelin and, 
hence, may transport both types of peptides. In fact, absorption 
studies of ghrelin- and desacyl-ghrelin-reactive IgG confirmed 
that they can bind both peptides (20).
Although some studies showed potential anorexigenic effects 
of desacyl-ghrelin (39, 40), its functional role in the regula-
tion of appetite remains uncertain including direct functional 
consequences of desacyl-ghrelin transport by IgG toward an 
unknown putative receptor (41). One alternative possibility is 
that desacyl-ghrelin may compete with acyl-ghrelin for protective 
IgG and, thereby, desacyl-ghrelin may have an anorexigenic effect 
by diminishing the ghrelin signaling via reduced formation of 
ghrelin/IgG immune complexes. Such possibility is of functional 
importance because starvation preferentially upregulates desacyl-
ghrelin, e.g., its ratios to acyl-ghrelin can be increased from 1:20 
in ad libitum fed mice to more than 1:70 in starved mice (Table 1) 
(17). Functional significance of the affinity kinetics changes in 
desacyl-ghrelin-reactive IgG is also difficult to interpret owning 
the same problem of the uncertain role of the desacyl-ghrelin 
peptide. Whether such changes are different from those obtained 
for acyl-ghrelin, it suggests that they may concern antibodies 
primarily targeting the desacylated N-terminal of ghrelin. It is, 
nevertheless, possible that decreased affinity of IgG for desacyl-
ghrelin may be favorable for desacyl-ghrelin competition with 
ghrelin for ghrelin-protective IgG and, hence, may result in 
reduced orexigenic activity of ghrelin. Furthermore, we have 
seen that KD values of desacyl-ghrelin IgG correlate positively 
with plasma levels of desacyl-ghrelin in animals with anorexia. 
Significant correlations were also found between plasma levels 
of desacyl-ghrelin reactive IgG and desacyl-ghrelin in patients 
with obesity and AN. Such correlations suggest that, similar to 
acyl-ghrelin, desacyl-ghrelin plasma concentrations can also be 
regulated by desacyl-ghrelin-reactive IgG.
GHReliN-ReACTive-igG iN OBeSiTY
Obesity is typically accompanied by increased food intake, sug-
gesting a possible role of ghrelin in the mechanism of hyperphagia 
(42). Indeed, obese subjects are more sensitive than lean subjects 
to increase their food intake after ghrelin administration (43). A 
particular situation may exist in non-hyperphagic HFD-induced 
obesity in mice that are less sensitive to the ghrelin’s orexigenic 
effect (44). In obese subjects, basal plasma levels of ghrelin meas-
ured as total ghrelin (acyl-ghrelin + desacyl-ghrelin) were found 
low (45, 46) or normal when measured selectively for acyl-ghrelin 
(13, 47, 48) (Table 1). Thus, increased food intake in common 
obesity cannot be related to increased ghrelin concentrations. 
There are, nevertheless, some exceptions showing elevated plasma 
ghrelin in hyperphagic obese patients with the Prader–Willi 
syndrome (PWS) (49) and hyperphagic obese Zucker rats (50, 
51). However, our study showed that obese Zucker rats display 
elevated desacyl-ghrelin, while acyl-ghrelin remains normal (16) 
(Table 1).
IgG in obese patients showed their ability to better protect 
ghrelin from degradation by an in vitro test and to increase its 
orexigenic activity after intraperitoneal administrations in rats 
FiGURe 3 | A schematic model summarizing the postulated role of ghrelin-reactive igG in ghrelin signaling in appetite control during normal and 
pathological conditions. According this model, acyl-ghrelin is protected by IgG from deacylation, therefore enhancing its orexigenic signaling to the brain. 
Changes in affinity of IgG for ghrelin in obese patients (increase) and in orexia nervosa patients (decrease) may enhance and diminish, respectively, ghrelin’s 
orexigenic effects. Desacyl-ghrelin may lower orexigenic effect via competing with ghrelin for ghrelin-reactive IgG resulting in increased ghrelin degradation. 
Moreover, decreased affinity of IgG for desacyl ghrelin may favor its dissociation from immune complexes and completion with ghrelin. The origin of changes in 
affinity of ghrelin- and desacyl ghrelin-reactive IgG is currently unknown but may potentially depend on antigenic stimulation from dysbiotic gut microbiota associated 
with long-term nutritional modifications in anorexia and obesity.
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(13). Such ghrelin’s enhancing properties of IgG in obesity can be 
explained by its increased affinity, as discussed above. Similarly, 
increased affinity of IgG for ghrelin was found in genetic animal 
models of obesity including both ob/ob mice (13) and Zucker 
rats (16) (Table 3). Obesity in both rodent’s models is due to the 
deficient leptin signaling and is characterized by hyperphagia. In 
mice that developed obesity after 2 months of HFD, IgG was also 
characterized by increased affinity for ghrelin (Table 3); however, 
these mice are not hyperphagic. In contrast to other animal 
models of obesity and to obese patients, HFD-obese mice also 
showed an increase in affinity of desacyl-ghrelin IgG (Table 4), 
but the significance of such change is not clear. The affinity kinetic 
properties of the association and dissociation rates leading to 
increased affinity were all different between humans and animal 
models of obesity including increased small Ka in obese patients, 
a decrease of small Kd in ob/ob mice and Zucker rats, and no 
significant changes in HFD obese mice (Table 3).
Although plasma levels of ghrelin-reactive IgG in obese 
patients and in all animal models reviewed here were slightly 
lower than in their non-obese controls (Table 2), the free/total 
ratios of ghrelin-reactive IgG were increased in patients and in 
Zucker rats (Table  2). Interestingly, a recent conference report 
revealed elevated plasma levels of ghrelin-reactive IgG in children 
with PWS (52). If confirmed, it will be the only so far known 
pathological conditions characterized by increased production of 
ghrelin-reactive IgG.
Taken together, these data suggest that obesity development 
leads to increased carrying properties of IgG for ghrelin in both 
obese humans and in animal models of obesity via increased 
affinity (Figure 1). Such changes in ghrelin-reactive IgG proper-
ties may represent a mechanistic factor underlying enhanced 
ghrelin signaling leading to hyperphagia and increased adiposity.
GHReliN-ReACTive-igG iN ANOReXiA
Anorexia can be a primary problem in patient with eating disor-
ders such as in restrictive AN, or it can be symptomatic during a 
chronic disease worsening its outcome. Ghrelin production and 
its plasma concentration are typically elevated during chronic 
starvation, accompanied or not by anorexia in both humans and 
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